Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside ...

To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a ...

Rectify Pharmaceuticals Inc. has conducted preclinical testing on RTY-694, an oral dual-targeted positive functional ...

The company analyzed genomic data provided by the Fred Hutch Cancer Center and compiled by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) to identify mutational signatures and ...

Potent siRNAs against B4GALT1 were designed in silico and screened in vitro (Huh7 cells, primary mouse, human hepatocytes) as well as in vivo (C57BL/6 mice) for the selection of a lead Galomic siRNA.

Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions.

The collaboration aims to identify a small molecule that targets mutant androgen receptor (AR) mRNA splicing and causes selective destruction of the disease-causing mRNA.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described pyrrolobenzodiazepine compounds reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Genzyme Corp. (Sanofi Genzyme) has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, multiple ...